BIIB · Biogen Inc.

Biogen’s acquisition of Apellis marks a strategic expansion into complement-mediated diseases and nephrology, anchored by two commercialized assets—SYFOVRE® (for geographic atrophy) and EMPAVELI® (for C3G, IC-MPGN, and PNH)—which generated $689 million in combined 2025 net product revenue. The transaction was executed via a tender offer followed by a short-form merger under Delaware law, eliminating the need for a shareholder vote and enabling rapid integration. The CVR structure introduces performance-based upside tied exclusively to SYFOVRE®’s commercial success, aligning incentives with long-term growth while limiting near-term cash outlay: no payment is due unless specific annual net sales thresholds are met, and each milestone triggers only once—even if exceeded across multiple years. The $2 billion term loan financing provides immediate liquidity without dilution, structured with staggered maturities (364 days and two years) to match anticipated near-term cash flow generation and integration timelines. Critically, the credit agreement includes a financial covenant that permits temporary leverage relief (up to 4.25:1.0) for four quarters post-close—a common accommodation for large acquisitions—indicating Biogen’s confidence in near-term earnings accretion and integration execution. Management explicitly states the deal will be accretive to Non-GAAP diluted EPS in 2027 and materially increase the company’s non-GAAP EPS compound annual growth rate through the end of the decade, underscoring its significance to the medium-term financial trajectory. The addition of Apellis’ nephrology infrastructure also accelerates Biogen’s launch readiness for felzartamab, with a pivotal Phase 3 readout expected in H1 2027—further extending the strategic runway beyond the acquired assets.